Reconciling immunotherapy and autoimmunity: not for the faint of heart

Immune checkpoint inhibitors, a class of immunotherapy, have revolutionised cancer therapy. Nearly half of all patients with metastatic cancer are eligible for immune checkpoint inhibitor treatment, and use for patients with early-stage cancers in the adjuvant setting is rapidly increasing.1 Immune checkpoint inhibitors exert anti-tumour effects by blocking immune checkpoints, which typically…

Read the full article here

Related Articles